Dosing Regimens | Indication | Classification | Intervention | Regimen Backbone | Patient number | OS | PFS | ORR | PSA50 | Clinical trail number | Reference |
---|---|---|---|---|---|---|---|---|---|---|---|
177Lu-J591 | M0CRPC | RDC | 177Lu-J591 + Keto + HC vs. 11In-J591(placebo) + Keto + HC | Keto + HC | 55 | - | 18.67mon | - | 82% (PSA90:50%) | NCT00859781 | [2] |
225Ac-J591 | mCRPC | RDC | 225Ac-J591 +Pemb + ARPI vs. Pemb + ARPI | Pemb + ARPI | 76 | - | 33% > 6 mon | - | 50% | NCT04946370 | [3] |
Lorigerlimab | mCRPC | DART | - | - | 42 | - | - | 25.7% | 28.6% (PSA90:21.4%) | NCT03761017 | [5] |
BPX-601 | mCRPC | CAR-T | - | AR antagonist + Taxane | 151 | - | - | 14.3% | 42.9% | NCT02744287 | [7] |
Capivasertib | mCRPC | AKTi | Capivasertib + docetaxel vs. placebo + docetaxel | Docetaxel | 790 | 31.5mon | 7.03 mon | - | 45% | NCT05348577 | [9] |